Clinical trials: Lipoprotein(a)
Atherosclerotic Cardiovascular Disease
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory…
- Trial name
- AZD0780-ABPM (NCT06692764)
- Testing
- AZD0780
- Where
- 26 sites in United States
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Cardiovascular Disease and Lipoprotein(a)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Trial name
- NCT07517263
- Testing
- Pelacarsen (TQJ230)
- Where
- 646 sites in United States, Argentina and 38 more
- Volunteers
- 5,700 people
- Sponsor
- Novartis Pharmaceuticals
MENINGOCOCCAL INFECTION
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children.
- Trial name
- NCT02531698
- Testing
- Bivalent rLP2086 Vaccine, Licensed pediatric hepatits A vaccine, Normal Saline
- Where
- 15 sites in Finland, Poland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI
- Trial name
- C-STAR (NCT05661552)
- Testing
- Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Yonsei University